Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MRNA expression analysis of human lung cancer cell line CUTO-3 and colorectal cancer cell line KM12-luc treated with TRK inhibitor CH7057288

ABSTRACT: mRNA expression analysis of human lung cancer cell line CUTO-3 and colorectal cancer cell line KM12-luc treated with TRK inhibitor CH7057288

PROVIDER: PRJNA490642 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

aCGH: Human SUM149-Luc triple-negative Inflammatory Breast Cancer cell line versus its metabolically adaptable variants MA1 and MA2

Project description:CGH array of MA1 and MA2 variant cells as compared to the parental SUM149-Luc breast cancer cell line. The MA1 and MA2 variants were isolated based on the ability of rare cancer cells to survive and grow without adding glutamine in culture medium. To gain insight into the characteristic of metabolically adaptable MA cells that enables them to survive severe metabolic challenge, i.e., prolonged lack of glutamine and other challenges [Singh et al., PLoS ONE 7: e36510, 2012], we analyzed CGH array to compare these cells with the parental SUM149-Luc (luciferase-transfected) cells. We analyzed two independently selected cell populations, one from 0.5 million parental cells (designated MA1) and one from 1 million parental cells (designated MA2). Comparing the MA1 and MA2 variants to the common parental SUM149-Luc cell line. One sample each.

2014-10-03 | E-GEOD-60015 | biostudies-arrayexpress

aCGH: Human SUM149-Luc triple-negative Inflammatory Breast Cancer cell line versus its metabolically adaptable variants MA1 and MA2

2014-10-03 | GSE60015 | GEO

mRNA expression analysis of human lung cancer cell line CUTO-3 and colorectal cancer cell line KM12-luc treated with TRK inhibitor CH7057288

Project description:CUTO-3 and KM12-luc cell lines were treated with DMSO or 1 uM CH7057288 for 4 and 24 hours. Cellular RNA was extracted, processed to generate an mRNA library, and sequenced from both ends of the library using HiSeq 2500 Sequencing System. RSEM software was used to align reads against RefSeq transcripts and calculate expression values (FPKM) for each gene.

2018-09-14 | GSE119900 | GEO

Identification of microRNA-27b target genes in breast cancer cell lines

2015-06-18 | GSE67631 | GEO

Identification of microRNA-27b target genes in breast cancer cell lines

Project description:To identify the microRNA-27b (miR-27b) target genes in luminal-type breast cancer cells, we performed the microarray analysis using miR-27b knockdown MCF7-luc cell line (MCF7-luc anti-miR-27b), miR-27b overexpressing MCF7-luc cell line (MCF7-luc miR-27b o.e.) and their contro cell line (MCF7-luc anti-NC). After establishing MCF7-luc anti-miR-27b, MCF7-luc miR-27b o.e. and MCF7-luc anti-NC using lentivirus vector, we performed the microarray analysis.

2015-06-18 | E-GEOD-67631 | biostudies-arrayexpress

breast cancer metastatic cell line

Project description:breast cancer metastatic cell line

| PRJEB97884 | ENA

Prostate Cancer Cell Line Transcriptomes

Project description:Prostate Cancer Cell Line Transcriptomes

| PRJNA871891 | ENA

The Poly (ADP-Ribose) Polymerase inhibitor Veliparib and Radiation Cause Significant Cell Line Dependent Metabolic Changes in Breast Cancer Cells

Project description:Breast tumors are characterized into different subtypes based on their surface marker expression, which affects their prognosis and treatment. For example, triple negative breast cancer cells (ER-/PR-/Her2-) show reduced susceptibility towards radiotherapy and chemotherapeutic agents. Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising results in clinical trials, both as single agents and in combination with other chemotherapeutics, in several subtypes of breast cancer patients. PARP1 is involved in DNA repair, apoptosis, and transcriptional regulation and an understanding of the effects of PARP inhibitors, specifically on metabolism, is currently lacking. Here, we have used NMR-based metabolomics to probe the cell line-specific effects of PARP inhibitor and radiation on metabolism in three distinct breast cancer cell lines. Our data reveal several cell line independent metabolic changes upon PARP inhibition, including an increase in taurine. Pathway enrichment and topology analysis identified that nitrogen metabolism, glycine, serine and threonine metabolism, aminoacyl-tRNA biosynthesis and taurine and hypotaurine metabolism were enriched after PARP inhibition in the three breast cancer cell lines. We observed that the majority of metabolic changes due to radiation as well as PARP inhibition were cell line dependent, highlighting the need to understand how these treatments affect cancer cell response via changes in metabolism. Finally, we observed that both PARP inhibition and radiation induced a similar metabolic response in the HCC1937 (BRCA mutant cell line), but not in MCF-7 and MDAMB231 cells, suggesting that radiation and PARP inhibition share similar interactions with metabolic pathways in BRCA mutant cells. Our study emphasizes the importance of differences in metabolic responses to cancer treatments in different subtypes of cancers.

2016-11-07 | MTBLS337 | MetaboLights

Identification of genes regulated by treatment with MEK inhibitor

Project description:In this study, we compared expression profiles between luciferase-expressing pancreatic cancer cell line MIA/luc with and without MEK inhibitor PD325901treatment in vivo.

2023-02-18 | GSE155549 | GEO

NCI small cell lung cancer cell line panel

Project description:NCI small cell lung cancer cell line panel

| PRJNA296061 | ENA